Instruction 1(b)

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

Washington, D.C. 20049

STATEMENT	OF CHANGES	IN BENEFICIAL	<b>OWNERSHIP</b>

OMB APPROVAL

OMB Number: 3235-0287

Estimated average burden
hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

											_					
1. Name and Address of Reporting Person*				2. Issuer Name and Ticker or Trading Symbol ISIS PHARMACEUTICALS INC [ ISIS ]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
PARSHALL B LYNNE					1010		.,	0201101	20 11 10	[ 1010 ]	<u> </u>	Directo	r		10% Ow	ner
(Last)	<b>(</b> E	iret)	(Middle)	}	Date of Earliest Transaction (Month/Day/Year)							X Officer (give title below)			Other (s below)	pecify
(Last) (First) (Middle) C/O ISIS PHARMACEUTICALS, INC.					01/30/2013						COO, Secretary					
2855 GAZELLE COURT																
2000 GIZELLE GOOKI					4. If Amendment, Date of Original Filed (Month/Day/Year)					6. In	6. Individual or Joint/Group Filing (Check Applicable					
(Street) CARLSI	BAD C.	A	92010							- 1 1	X Form filed by One Reporting Person Form filed by More than One Reporting					
(City)	(S	tate)	(Zip)		Person Person									9		
		Tal	ole I - Non-I	Deriva	tive S	ecuritie	es Ac	cquired, Di	sposed o	f, or Ber	eficially	/ Owned				
1. Title of Security (Instr. 3)  2. Transa Date (Month/D			ate	Execution Date,		Code (Inst	n Disposed	urities Acquired (A) or sed Of (D) (Instr. 3, 4 a		5. Amount of Securities Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	: Direct I Indirect I str. 4)	7. Nature of Indirect Beneficial Ownership		
			Code V			Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)				Instr. 4)			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
Security or Exercise (Month/Day/Year) if any		Execution Date	Coc	ransaction of code (Instr. Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)  7. Title and An of Securities Underlying Derivative Sec (Instr. 3 and 4)		es g Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
				Cod	le V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
Restricted Stock Units	(1)	01/30/2013	01/30/2013	A		10,380		(2)	(2)	Common Stock	10,380	\$0	10,38	0	D	
Employee Stock Option (right to	\$14.69	01/30/2013	01/30/2013	A		62,280		01/02/2014 <sup>(3)</sup>	01/29/2020	Common Stock	62,280	\$0	62,28	0	D	

## **Explanation of Responses:**

- 1. Each restricted stock unit represents a contingent right to receive one share of Isis common stock, or its equivalent cash value.
- 2. Grant 1/30/2013 to reporting person of Restricted Stock Units under the Isis Pharmaceuticals, Inc, 2011 Equity Incentive Plan. Restricted Stock Units vest in four equal annual installments, the first installment vesting on January 15, 2014. Upon vesting, the restricted stock units will be paid out in whole shares of Isis common stock or cash as may be determined by the Company. The RSU shall be fully vested on January 15, 2017. The RSU is vested as to 0 shares on January 30, 2013.
- 3. Grant of 1/30/2013 to reporting person of stock options under the Isis Pharamceuticals, Inc. 1989 Stock Option Plan. 25% of the shares subject to the option will vest and become exercisable on 1/2/2014. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments, at the rate of 15,570 shares per year. The option is exercisable as to 0 shares on 1/30/2013.

## Remarks:

/s/B. Lynne Parshall

\*\* Signature of Reporting Person

<u>02/01/2013</u> Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.